In Alnylam’s Search For A Mass-Market Treatment, A Twice Yearly Blood Pressure Injection Could Fit The Bill
Crucial Phase II Readouts This Year
Alnylam is using its RNA interference technology to target hypertension, which could create a true mass-market cardiovascular blockbuster drug for the firm – but upcoming Phase II data will need to be compelling.
